Senores Pharmaceuticals Limited has informed the Exchange about Submission of Reconciliation of Share Capital Audit Report for the quarter ended June 30, 2025 under Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Senores Pharmaceuticals Limited has filed its quarterly Reconciliation of Share Capital Audit Report with the stock exchanges as required under SEBI Regulation 76. The company has an issued and listed equity share capital of 4,60,53,588 shares with a face value of Rs. 10 each, fully matching across issued, listed, and total categories. All shares are held in dematerialized form — 57.21% (2,63,48,304 shares) with NSDL and 42.79% (1,97,05,284 shares) with CDSL, with zero shares in physical form. The report, certified by Practicing Company Secretary Mr. Tapan Shah, confirms no changes in share capital during the quarter, the Register of Members is updated, and there are no pending demat requests beyond 21 days.
This is a routine quarterly compliance filing mandated by SEBI and carries no material impact on shareholders or the stock price. The clean report with 100% dematerialized holdings and no discrepancies reflects good corporate governance practices.